Genmab Reports Q3 DARZALEX Net Sales Of $4.239B

Genmab reported that worldwide net trade sales of DARZALEX reached $4.239 billion in Q3 2026, with $2.528 billion from the U.S. and $1.711 billion from international markets. The company earns royalties on these sales under its exclusive license agreement with Johnson & Johnson for the development and commercialization of daratumumab.